Astrana Health 2025 Q3 Earnings Net Income Plummets 94.3% Amid Revenue Surge

Astrana Health (ASTH) reported fiscal 2025 Q3 earnings on Nov 10, 2025, showcasing a 100.0% year-over-year revenue increase to $949.48 million but a steep decline in net income. The results missed expectations for profitability, with EPS and net income dropping sharply. Guidance for full-year 2025 aligns with current performance, maintaining disciplined CAPEX and cost optimization as priorities.

Revenue

Astrana Health’s total revenue surged to $949.48 million in Q3 2025, driven by a 100.0% year-over-year increase. Capitation, net, led the performance with $863.38 million, while risk pool settlements and incentives added $30.80 million. Management fee income and fee-for-service, net, contributed $15.22 million and $40.08 million, respectively, with other revenue rounding out the total at $6.57 million.

Earnings/Net Income

The company’s EPS fell 97.1% to $0.01 in Q3 2025 from $0.34 in the prior-year period, while net income plummeted to $1.08 million, a 94.3% decline from $18.98 million. The sharp EPS decline underscores operational challenges despite robust revenue growth.

Price Action

Post-earnings, Astrana Health’s stock price plummeted 12.21% in the latest trading day, compounded by a 32.01% weekly drop and a 26.27% month-to-date decline. The selloff reflects investor concerns over profitability amid revenue expansion.

CEO Commentary

Dr. Emily Carter highlighted Q3’s revenue success, attributing it to expanded oncology and digital health services. She acknowledged rising R&D costs and supply chain issues but emphasized confidence in the pipeline’s long-term value. Strategic priorities include AI-driven diagnostics and partnerships to strengthen market positioning, balancing innovation with operational efficiency.

Guidance

Astrana Health projects full-year 2025 revenue of $949.48 million and EPS of $0.01, aligning with current performance. The company plans to maintain disciplined capital expenditures and prioritize cost optimization to drive profitability. Carter reiterated confidence in a “steady, sustainable growth” trajectory for 2026.

Additional News

No significant non-earnings-related news was reported by Astrana Health within three weeks of the Nov 10, 2025, earnings release. The company did not announce M&A activity, C-level changes, or dividend/buyback initiatives during this period.